The findings highlight the potential of the interleukin-23 inhibitor to address a notoriously difficult-to-treat manifestation of psoriasis.

The findings from the long-term extension ADjoin study will be presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting.

Preview the posters and abstracts covering atopic dermatitis advances from Arcutis, Incyte, Lilly and Sanofi/Regeneron.

There are 3 classes of nonsteroidal topical therapies for atopic dermatitis that target the specific underlying pathophysiology of the skin disease. Shahriari provides a primer as physicians prepare for AAD 2025.

AAAAI 2025: Data from the ANCHOR-1 and ANCHOR-2 phase 3 trials show improvements in nasal polyp size and obstruction for depemokimab with twice-yearly dosing vs placebo.

They are a Janus kinase (JAK)1/JAK2 inhibitor, a phosphodiesterase-4 inhibitor, and an investigational aryl hydrocarbon receptor agonist. Learn more about each.

Safety findings from the phase 3 OUtMATCH trial were notable, including no adverse events for omlizumab vs 30.5% for OIT and epinephrine use for 0% vs 37.3%, respectively.

Participants (aged 6 to 17 years) receiving neffy vs standard treatments had fewer skin, gastrointestinal, and respiratory symptoms at 15, 5, and 5 minutes, respectively.

Shahriari, assistant clinical professor of dermatology at Yale University School of Medicine, says greater understanding of the condition has expanded the population for the diagnosis.

Although many women experience symptoms of perimenopause between ages 30 and 35, the majority do not seek medical attention for up to 2 decades, a new study reveals.

Up to 80% of atopic dermatitis is managed in primary care but some patients will need a higher level of care. Dr Mona Shahriari discusses factors that point to referral.

Not all atopic dermatitis requires treatment by a specialist, says this dermatologist, and she collaborates regularly with her primary care colleagues.

AAAAI 2025: Phase 2 study results showed POIT with home-measured peanut products was not only highly effective but also posed few risks.

Tips cover biologic agents and hepatitis B, 5-FU plus calcipotriene for AK, a triple treatment package for post-acne postinflammatory hyperpigmentation, and more.

Neal Bhatia, MD, highlighted updates in the management of actinic keratosis, emphasizing strategies to reduce skin cancer risk and improve patient outcomes.

Cheri Frey, MD, explored novel active ingredients, advancements in skin care formulations at the Midwinter Clinical Derm Conference.

Susan C Taylor, MD, is internationally recognized for her expertise in dermatologic conditions in skin of color and spoke about avoiding photodamage at the Midwinter Clinical Derm Conference.

Established therapies for these common disorders don't always lead to optimal results; experts offer new evidence-based options that may help.

Systemic therapy for nail disorders, including biologics and JAK inhibitors, is gaining favor; learn more about early diagnosis and aggressive treatment from an expert.

Theodore Rosen, MD, underscored the critical need for responsible antibiotic use in dermatology to combat the accelerating crisis of drug-resistant infections.